Under the agreement, Astellas acquired 100% of the equity in Ganymed
, and in addition, Ganymed
's shareholders were eligible to receive up to USD 940.
The acquisition of Ganymed
will enable Astellas to further expand our oncology presence by adding a late-stage antibody asset with the potential to establish a new pillar following XTANDI," commented Yoshihiko Hatanaka, President and CEO, Astellas.
Ozlem Tureci, chief executive officer and co-founder of Ganymed
said, "I am impressed by the competence, commitment and vision of Astellas.
Upon completion of the transaction, which is expected in the coming weeks, Ganymed
will become a wholly owned subsidiary of the Japanese firm.
With completion of the transaction, Ganymed
became a wholly owned subsidiary of Astellas.
Pharmaceutical company Astellas Pharma Inc (TSE: 4503) and Ganymed
Pharmaceuticals AG, a German biopharmaceutical company that focuses on the development of antibodies against cancer, announced on Friday that the shareholders of both companies have agreed the acquisition of Ganymed
Global Markets Direct's, 'Ganymed
Pharmaceuticals AG - Product Pipeline Review - 2014', provides an overview of the Ganymed
Pharmaceuticals AG's pharmaceutical research and development focus.
23 October 2013 - German anticancer drugs developer Ganymed
Pharmaceuticals AG said earlier this week that its monoclonal antibody, IMAB362, had received orphan drug status from the US FDA and the European Medicines Agency (EMA) as a therapy of pancreatic cancer.
Bionucleon Srl, GANYMED
Pharmaceuticals AG, Ora Bio Ltd.
87m to (EUR 422m) acquire Mainz, Germany-based biopharmaceutical company Ganymed
Pharmaceuticals AG, the company said.
JAPAN'S ASTELLAS TO ACQUIRE GERMAN DRUGMAKER GANYMED
FOR EUR 422M
M2 EQUITYBITES-October 31, 2016-Japan's Astellas to Acquire German Drugmaker Ganymed
for EUR 422m